Allele Biotechnology Inc. (ALLELE) in San Diego, California, and Mimotype in Berlin, Germany, have announced a collaboration focused on expanding the frontiers of fluorescent protein applications in materials science and bio-integrated technology.
This partnership is enabled through a licensing agreement granting Mimotype access to the red fluorescent protein mScarlet3, originally developed at the University of Amsterdam and exclusively licensed to Allele. Mimotype are now working to functionalize and embed high performance proteins like mScarlet3 into next-generation materials, for commercial and research applications beyond traditional bioimaging.
“Allele’s licensing of mScarlet3 forms the foundation for a collaboration we’re incredibly excited about,” said Claudio Flores, CEO of Mimotype. “By combining our fluorescent protein pipeline with Allele’s pioneering work in highly performant variants, we’re building new tools that reimagine fluorescent proteins as programmable light within advanced materials.”
Mimotype’s development efforts are currently focused on exploring the magnetoresponsive properties of mScarlet3. By embedding fluorescent proteins into soft material systems, the team is developing materials that transduce magnetic stimuli into optical signals. These systems unlock new possibilities for biosensors, responsive diagnostics, and smart photonic devices, particularly in fields such as chronic disease monitoring and non-invasive biointerfaces.
Allele has developed and possesses some of the most popular fluorescent proteins that have been integrated into dozens of different sensors for cell fate and function analysis. Similar to its position in the cell research marker field, Allele has also established itself to be the source of industry iPSC lines produced in its own cGMP facility in San Diego and licensed by leading cell therapy developers such as Astellas and KPharma.
“We are glad to see how the best fluorescent proteins we have are going to be used in unconventional ways and by such a highly innovative team like Mimotype’s. I believe there will be unprecedented integration between photonic soft materials they are working on and the regenerative medicine field, including 3D bioprinted organs, that we are working on in the near future,” said Jiwu Wang, Ph.D., CEO of Allele Biotech.
About Mimotype
Mimotype is building the optical layer of the bio-nanotech future. By engineering and functionalizing fluorescent proteins, the company enables a new class of sustainable, programmable, and biocompatible light-emitting materials. Its custom biofabrication pipeline spans the full cycle, from protein design to optical device integration, enabling scalable, cost-effective production of advanced bio-optical materials. By combining fluorescent proteins with natural polymers like silk and cellulose, Mimotype creates bio-inspired materials for applications across biosensing, photonics, and quantum biology.
About Allele Biotechnology
Allele Biotechnology and Pharmaceuticals, Inc. is a San Diego-based company that explores the mechanisms of biological processes to develop technologies and products for biomedical research and therapy development. ALLELE’s mission is to increase accessibility to superior research and clinical assets by offering cutting edge technologies in individual products and fully integrated platforms. The company is the exclusive licensee of mScarlet3 and operates a state-of-the-art cGMP facility supporting translational cell and molecular platforms. Learn more at www.allelebiotech.com.